Several studies highlight the high efficacy of guselkumab (anti-IL23) and secukinumab (anti-IL17) for the control of severe psoriasis, in addition to the control of psoriatic arthritis symptoms [13], which other older biologics do not resolve. This evidence concerns the gene IL37 and psoriatic arthritis.